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ABSTRACT
Introduction: Chronic thoracic aortic aneurysm
(CTAA) affecting the arch or descending aorta is an
indolent but life-threatening condition with a rising
prevalence as the UK population ages. Treatment may
be in the form of open surgical repair (OSR) surgery,
endovascular stent grafting (ESG) or best medical
therapy (BMT). Currently, there is no consensus on the
best management strategy, and no UK-specific
economic studies that assess outcomes beyond the
chosen procedure, but this is required in the context of
greater demand for treatment and limited National
Health Service (NHS) resources.
Methods and analysis: This is a prospective,
multicentre observational study with statistical and
economic modelling of patients with CTAA affecting
the arch or descending aorta. We aim to gain an
understanding of how treatments are currently
chosen, and to determine the clinical effectiveness
and cost-effectiveness of the three available treatment
strategies (BMT, ESG and OSR). This will be
achieved by: (1) following consecutive patients who
are referred to the teams collaborating in this
proposal and collecting data regarding quality of life
(QoL), medical events and hospital stays over a
maximum of 5 years; (2) statistical analysis of the
comparative effectiveness of the three treatments;
and (3) economic modelling of the comparative cost-
effectiveness of the three treatments. Primary study
outcomes are: aneurysm growth, QoL, freedom from
reintervention, freedom from death or permanent
neurological injury, incremental cost per quality-
adjusted life year gained.
Ethics and dissemination: The study will generate
an evidence base to guide patients and clinicians to
determine the indications and timing of treatment, as
well as informing healthcare decision-makers about
which treatments the NHS should provide. The study
has achieved ethical approval and will be
disseminated primarily in the form of a Health
Technology Assessment monograph at its
completion.
Trial registration number: ISRCTN04044627.
INTRODUCTION
The clinical problem
Chronic thoracic aortic aneurysm (CTAA) is
deﬁned by dilation of the thoracic aorta to
beyond 50% of normal. Dilation weakens the
aortic wall leading to aortic rupture, dissec-
tion and/or death. CTAA also increases the
risk of non-fatal complications such as stroke,
renal failure or paraplegia. There are esti-
mated to be 3000–8000 new cases of CTAA in
the UK each year.1 The natural history of
CTAA is not clearly understood, however,
because patients usually remain asymptomatic
until presentation with rupture, dissection or
Strengths and limitations of this study
▪ As an observational study, we anticipate strong
recruitment and a study that truly reflects UK
practice.
▪ Since the study observed patients through the
watchful waiting period into their treatment and
beyond, we will be able to capture the elements
that contribute towards decision-making.
▪ The planned Delphi exercise will deliver a con-
sensus on which patients would be best served
by which treatments.
▪ Being a UK-wide study, we will also be able to
report on geographic variation in treatment avail-
ability and resource use.
▪ The planned health economic exercise is a par-
ticular strength of the study and will deliver a
comprehensive cost-effectiveness analysis of the
treatments available for chronic thoracic aortic
aneurysm.
▪ Patient pathways may not be as clearly deli-
neated as in a trial setting. We anticipate, there-
fore, that the interpretation of outcomes by
group will need careful analysis. Sophisticated
statistical modelling methods and a Delphi con-
sensus exercise are planned to allow for this.
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death. CTAA can be detected prior to such events on
imaging scans performed for other reasons. In these
scenarios, there is a lack of evidence regarding what may
happen without procedural intervention.
The rate of growth of CTAA has been estimated at
0.1 cm/year from Professor Elefteriades’s Yale database
of 3000 patients with CTAA. His research demonstrated
that aneurysm size (when indexed to the patient’s size)
is proportional to the risk of rupture (table 1).2 While
the aneurysm is small, clinicians usually advise a period
of watchful waiting (WW) during which the patient will
have serial CT scans or MRI to monitor the size of the
aneurysm. Medications will be started to control blood
pressure and reduce the risk of rupture, dissection or
death. Nonetheless, these (and other non-fatal) compli-
cations may still occur when the aneurysm is small. The
risk factors for this are not clearly understood. The data
we do have on the natural history of small aneurysms are
retrospective. As such, it is likely to underestimate the
risk of larger aneurysms (where patients are followed up
for very short periods of time) and overestimate the risk
of smaller aneurysms (where patients may be followed
up for years). Therefore, a prospective study is required
to describe the natural history of CTAA in asymptomatic
patients prior to intervention.
As aneurysms grow, there is an increasing risk of fatal
complications. Treatment to reduce this risk can be in
the form of best medical therapy (BMT), endovascular
stent grafting (ESG) or open surgical repair (OSR), and
is justiﬁed when the risk associated with intervention is
perceived to be less than the risk of rupture, dissection
or death. The risk of rupture is mostly (but not entirely)
dependent on aneurysm size.2 The risk of intervention,
however, is inﬂuenced by a variety of factors and is differ-
ent for every patient. Therefore, specialist multidisciplin-
ary teams play a key role in discussing the risk-beneﬁt
proﬁle for each patient before recommending a treat-
ment pathway. Ultimately, the choice of treatment is
made by the patient after appropriate explanation and
discussion.
At present, there is no national or international
guideline addressing patient selection for BMT, ESG or
OSR. In the absence of such a guideline, the decision
(BMT, ESG or OSR) is made after considering patient
factors (including age, comorbidities and personal
choice) and aneurysm factors (including indexed size,
collagen vascular disorder and anatomy/morphology)
(ﬁgure 1).
Survey responses from the clinicians in this collabor-
ation demonstrated that there is signiﬁcant subjectivity
in this decision-making process. At present, ESG tends
to be performed for older patients with more comorbid-
ity, since it is a less invasive intervention. OSR tends to
be preferred for younger patients with less comorbidity,
since they are more able to withstand the operation and
it is felt that OSR may reduce the chance of further
interventions in the future. On the basis of current prac-
tice, however, there are many patients who are consid-
ered equally appropriate for ESG and OSR based on
patient and aneurysm factors (ﬁgure 2). Indeed, some
of these patients may instead choose BMT. In this study,
we will compare the clinical effectiveness and cost-
effectiveness, as well as quality of life (QoL) outcomes of
BMT, ESG and OSR among those patients thought to be
suitable for more than one treatment.
Table 1 Risk of rupture according to indexed aortic size
Indexed aortic size,
cm/m2
Risk of rupture, dissection
or death, % per year
<2.75 4 (low risk)
2.75–4.25 8 (moderate risk)
>4.25 20 (high risk)
Figure 1 The decision-making
process for treatment for chronic
thoracic aortic aneurysm (CTAA;
ESG, endovascular stent grafting;
OSR, open surgical repair).
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Existing literature
OSR has been the mainstay of treatment for CTAA for
the past four decades. It is a complex operation requir-
ing a large incision, but has been demonstrated to
reduce mortality and can be performed reproducibly in
cardiac surgical centres. Techniques have improved, but
OSR still carries a risk of approximately 5% mortality
and approximately 10% paraplegia. ESG for CTAA is a
newer (approximately 10–15 years old) and less invasive
technique. It has been shown to be technically feasible,
and some studies have even demonstrated aneurysm
shrinkage. It is, however, most often selected for patients
who have been turned down for OSR. It cannot be per-
formed in all patients due to speciﬁc technical require-
ments of the procedure. It is also relatively resource
intensive as it requires a hybrid theatre and an appropri-
ate theatre team.
Table 2 summarises the largest, most recent and
longest running studies that compare clinical and cost
outcomes for ESG and OSR.3–8 These were chosen as rep-
resentative of the wider literature in the course of an
informal literature review performed by the authors,
searching PubMed, MEDLINE and the Cochrane
database, using terms including (but not exclusively)
‘thoracic aneurysm’, ‘clinical outcomes’ and ‘cost-
effectiveness’. All the studies acknowledge differences
between surgical and endovascular cohorts which may
inﬂuence the results that are reported. Stent grafting
tends to be chosen for older patients with more
comorbidity, many of whom were denied surgical repair.
Despite its use on older, sicker patients, the risk of death,
paraplegia or other complications appears to be less for
ESG than for OSR. The need for reintervention,
however, appears to be higher after ESG due to technical
failures of the stent that accrue over time (16% at
4 years,9 23% at 5 years, 37% at 8 years10), and with each
reintervention there is an added risk of complication
either due to the increased complexity of the procedure
or deteriorating health of the patient.
There are few studies comparing the cost-effectiveness
of ESG against OSR in the context of CTAA. These
papers are also summarised in table 2. All the studies
that appear in table 2 consider only in-hospital cost,
thereby excluding the cost of reintervention. No formal
economic evaluation has been performed. Therefore,
there is a lack of economic data to guide decision-
makers in the choices they must make in allocating the
scarce resources available. A systematic literature review
will be performed and included as part of the ﬁnal
report of this study.
Why is this research needed now?
In the past 5 years, data have been published (mainly
from US cohorts) regarding the clinical outcomes of ESG
at a decade of follow-up. It has been shown to be clinic-
ally effective for some patients, but with an acknowledged
complication rate of 10–15% (refs 3 and 4). Currently,
there is no consensus on the best management strategy
and timing of different interventions, and no UK-speciﬁc
economic studies that assess outcomes beyond the
chosen procedure. With this in mind, there is a need to
generate further evidence regarding the cost-
effectiveness of ESG, OSR and indeed BMT. This evi-
dence is not currently adequate, but is urgently needed
in the context of greater demand for treatment (an
ageing population with a rising prevalence of CTAA) and
limited National Health Service (NHS) resources.
METHODS AND ANALYSIS
Design
This is a prospective, multicentre, observational study
with statistical and economic modelling of patients with
a chronic aneurysm of the thoracic aortic arch (TAA) or
descending thoracic aorta (DTA). Both these conditions
are a subset of CTAA. The ascending aorta may also
become aneurysmal, but is not considered in this study
as ESG is rarely undertaken for this condition.
Figure 2 The expected UK
populations (BMT, best medical
therapy; ESG, endovascular stent
grafting; OSR, open surgical
repair; WW, watchful waiting).
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Table 2 Summarised literature review
Study description Key results Comments
Desai et al, JTCVS 20123
Retrospective cohort study
106 ESG vs 45 OSR
10-year follow-up
In-hospital mortality ESG 2.6%, OSR 6.7% open; p=0.1 In multivariate analysis, age, COPD, diabetes and renal failure
were predictors of late mortality but technique (ie, ESG vs
OSR) was not
Paralysis/paraparesis ESG 3.9%, OSR 7.1%; p=0.2
10-year survival Similar between groups (p=0.5)
Freedom from reintervention ESG 85% at 10 years, OSR 0% at 10 years, p=0.2
Gopaldas et al, JTCVS 20124
Retrospective cohort study
2563 ESG vs 9106 OSR
2-year follow-up
All-cause complications ESG 22.9%, OSR 37.6%, p<0.001 The patients who had undergone ESG were older (mean age
69.5 vs 60.2, p<0.001) and had higher Deyo comorbidity
scores
The unadjusted cost for patients with ESG appeared to be
lower, but did not prove to be significantly so on multivariate
analysis
The cost analysis only accounts for in-hospital cost for the
index procedure
Length of stay ESG 7.7 days, OSR 8.8 days, p=1
In-hospital mortality ESG 2.3%, OSR 2.3%, p=1
Average hospital charges ESG US$46 636, OSR US$48 974,
p<0.05
Orandi et al, 20095
Retrospective cohort study
763 OSR patients vs 267 ESG
patients
In-hospital mortality ESG 7.7%, OSR 6.4% (p=.49) The authors state that in-hospital costs were the same for
patients with ESG and OSR (data not published for both
groups), but this is assessed only in a subgroup of patients
with no complications
All-cause complications ESG 20.4%, OSR 33.1% (p<0.001)
Mean length of stay ESG 5 days, OSR 7 days, p=0.0015
Bavaria et al, 20076
Multicentre retrospective
comparative trial
17 participating sites
94 OSR patients vs 137 ESG
patients.
2-year follow-up (25.8 months
(ESG) and 24.9 months (OSR))
Perioperative mortality ESG 2.1% vs OSR 11.7% p<0.001
In-hospital morbidity ESG group had a significantly lower incidence of
respiratory failure (4% vs 20%, p<0.001), renal failure
(1% vs 13%, p=0.01) and paraplegia/paraparesis (3%
vs 14%, p=0.003)
The ESG group had a significantly higher incidence of
peripheral vascular complications (14% vs 4%,
p=0.015)
Mean ICU length of stay ESG 2.6 days vs OSR 5.2 days, p<0.001
Mean hospital length of stay ESG 7.4 days vs OSR 14.4 days, p<0.001
Estimated 2-year survival 78% ESG vs 76% OSR
Reinterventions 3 reinterventions in the ESG group within 2 years.
None in the OSR group
Dick et al, ATS 20087
Retrospective cohort study
52 ESG vs 70 OSR patients
Mean follow-up of 34 months
Perioperative mortality ESG 8%, OSR 9%, p=0.25 Significant proportions (14–20%) of interventions were
performed for acute rupture/dissection, ie, non-elective
Also demonstrated lower incidence of pneumonia in the ESG
group
Does not capture preintervention QoL or demonstrate the
expected early difference in QoL between ESG and OSR
Hospital length of stay ESG 11.6 days, OSR 18.3 days, p<0.001
QoL score at 3 years (measured
by SF-36 and hospital anxiety
and depression scores)
SF-36: ESG 83, OSR 93, p=0.66. Anxiety score: ESG
5, OSR 4, p=0.79. Depression score: ESG5, OSR 3.4,
p=0.09
Narayan et al, EJCTS 20118
Retrospective cohort study
49 ESG (45% of these were for
aneurysm) vs 35 OSR (53% of
these were for aneurysm)
Total cost £16 694 ESG vs £15 045 OSR p=0.41 Small study of within-hospital NHS costs only. Lack of detail
regarding costing and operative indications. No long-term cost
analysis for the lifetime of the patient. No wider costs including
personal social services. No preference-based quality of life
estimate
COPD, chronic obstructive pulmonary disease; ESG, endovascular stent grafting; ICU, intensive care unit; NHS, National Health Service; OSR, open surgical repair; QoL, quality of life.
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The adult aorta is expected to measure 2.39–2.98 cm11
at the point of the mid-DTA. Therefore, as a rough
guide, aneurysm of the TAA or DTA is generally diag-
nosed at 4 cm.
Patient enrolment
Each multidisciplinary team (MDT) in this collaboration
will send information leaﬂets about the ETTAA study to
general practitioners, cardiologists, cardiothoracic and
vascular surgeons in their catchment areas, advertising
the study and inviting referrals of all patients with CTAA
≥4 cm. Within the MDT forum, the clinical group will
identify those patients who are eligible for the study.
These patients will be approached by the investigating
team local to them, led by the local principal investigator
(PI) and assisted by a research nurse. Patients who give
their consent to participate will be enrolled in the study
by either the local PI or the local research team. By
screening consecutive patients referred to the MDTs,
rather than screening patients referred only to single spe-
cialists, we hope to minimise referral bias. We appreciate
that we may miss some patients who are never referred to
the MDT, but we hope that sending information leaﬂets
and raising awareness of aortic MDTs within the primary
care community will help support referral into the MDT
system. Current practice is that specialists in the MDTwill
recommend either WW (if the risk of rupture is low) or
intervention in the form of BMT, ESG or OSR when the
risk of rupture is moderate-high (table 3). We recognise
that patients who initially elect for a conservative option
may later change their opinion, and this will be captured
as a crossover from BMT to ESG/OSR. Patients enrolled
in the study will be observed from the time of referral, up
to and beyond treatment (BMT, ESG or OSR) until the
study concludes at 5 years (median follow-up for this
cohort therefore being 3 years).
Measurement of cost and outcomes
Primary study outcomes are:
▸ Aneurysm growth;
▸ QoL;
▸ Freedom from reintervention;
▸ Freedom from death or permanent neurological
injury;
▸ Incremental cost per quality-adjusted life year
(QALY) gained.
These in turn will be derived from a fuller list of para-
meters (table 4). These parameters have been chosen by
the collaborators on the basis of current literature and
previous risk modelling. As described below, primary
outcomes will be compared in patients thought to be
suitable for more than one treatment. In non-
comparable patients, the primary outcomes will be
described.
All data collection will be prospective, performed by
the research team local to the patient, either in person
during a hospital/clinical attendance or over the
telephone. Procedure-related complications/clinical
outcomes will be collated from medical records, and
QoL will be determined by patient-completed EQ-5D-5L
questionnaires. Clinical outcomes and EQ-5D-5L scores
will be recorded at initial review (time zero), 3, 6, 12, 18
and 24 months, and then annually until the follow-up
concludes at 5 years. If a patient undergoes ESG or
OSR, the ‘clock’ will be reset on the day of intervention.
Clinical outcomes and QoL data will then be collected
preprocedure, at discharge, 3, 6, 12, 18 and 24 months,
and then annually after intervention until the follow-up
concludes. This will allow a comparison of QoL in the
early period after ESG or OSR since there is likely to be
a signiﬁcant difference in this phase.
In contrast, technical outcomes and aneurysm size will
be assessed less frequently since they require interval CT
scan or MRI. These will be performed in line with
current practice guidelines (minimum once per year,
with further scans performed as clinically indicated) and
supported by morphological analysis in the Corelab to
reduce reporting bias. The Corelab will be run by St
Georges Hospital and led by Professor Matt Thompson.
It is a facility where anonymised scans will be analysed
and reported by independent experts to ensure consist-
ent and uniform reporting to deﬁned standards. If dis-
crepancies are found in excess of the expected
interobserver error, then the provenance of the scans
will be traced back and investigated. In addition to valid-
ating aneurysm growth rates, the Corelab will also
provide an independent analysis of technical outcomes
following intervention.
The primary outcomes will be reported at the comple-
tion of the study, with an anticipated median follow-up
of 3 years.
Comparison of treatment groups for clinical effectiveness
On the basis of initial audits of the participating centres,
there is substantial heterogeneity among clinicians in
the timing and/or nature of interventions, with some
centres favouring ESG and others focused on OSR. This
will create a substantial overlap in characteristics
between the populations of patients undergoing ESG
and OSR. Therefore, it will be possible to compare treat-
ment groups for clinical and cost-effectiveness of these
two groups based on the actual treatment undertaken.
This will require methods speciﬁcally designed to
address bias inherent in observational studies, and these
are described in more detail in the statistical analysis
section below.
The overlap between populations assigned to medical
therapy and the intervention groups is less clear. If there
is substantial heterogeneity among clinicians in the
patient characteristics of this group, then clinical and
cost-effectiveness comparisons can be undertaken using
methods similar to the ESG-OSR comparison above. On
the other hand, if all clinicians intervene with either
ESG or OSR at a similar stage in aneurysm development,
and for similar patients, then WW and BMT patients will
form two distinct groups, in terms of aneurysm
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morphology, and the deﬁned population and their out-
comes will be reported. No comparisons will be
undertaken.
Comparison of treatment groups for cost-effectiveness
This will involve both a ‘within’ study patient-level ana-
lysis and a model-based analysis to extrapolate outcomes
into the longer term. The within-study analysis will take
the form of a cost-utility analysis with outcomes reported
in terms of incremental cost per QALY gained, and also
costs and QALYs for each intervention compared. The
methods to conduct this analysis are explained in the
economic analysis section below but will need to address
the same issues and hence use methods similar to those
required to assess clinical effectiveness from an observa-
tional study as noted in (3) above. The base case analysis
will compare similar groups of patients where each
group initially receives one of the health technologies
under investigation. The long-term analysis will be based
on a Markov model. The model structure will describe
the sequence of events from the point where an individ-
ual receives one of the interventions under investigation.
It will include perioperative and postoperative complica-
tions for surgical interventions and side effects of
medical treatments. It will also describe the potential
sequence of events that might occur over time. The
development of the structure of the model will be
informed through consultation with the study team and
using information from the literature. The methods
used to populate the model and analyse the data are
described in the economic analysis section below.
Inclusion/exclusion criteria
Inclusion criteria: All patients who are over 18 years of age
with chronic aneurysm of the arch or DTA and who can
provide valid written consent are eligible for the study.
Exclusion criteria: Patients with acute dissection or malper-
fusion syndromes (such as myocardial infarction, acute
stroke or limb ischaemia) will be excluded. This is
because the clinical picture signiﬁes a type B acute
aortic syndrome, and the role of surgery and stenting in
this context has been investigated by others.
Data collection
The data to be collected is shown in table 4. Data will be
collected from a variety of sources, but mainly medical
records and patient feedback questionnaires for clinical
events and QoL; CT scan/MRI for aneurysm morpho-
logical data; unit costs of services used will be obtained
from parallel costing exercises and use study-speciﬁc esti-
mates, NHS reference costs, manufacturer/supplier costs
and other publicly available data.
Ethics and dissemination
The study will culminate in a Health Technology
Assessment monograph describing the study and its
results in detail, which will allow us to make recommen-
dations for practice and policy in the UK. We anticipate
a number of publications describing:
▸ Changes in aneurysm size over time;
▸ Selection criteria for ESG, OSR and BMT;
▸ Factors affecting outcomes after ESG and OSR;
▸ Comparative clinical outcomes after ESG and OSR in
those patients who were eligible for both treatments;
▸ QoL and cost-effectiveness in patients for whom
more than one treatment is appropriate;
▸ Geographical variation in patterns of disease.
Furthermore, we will provide an analysis of patient-
speciﬁc and aneurysm-speciﬁc factors (if there are any)
which predict good or poor outcome. It is hoped that
identiﬁcation of such factors will allow us to propose a
draft guideline for the indications for BMT, ESG or OSR
in patients with CTAA. We also anticipate that there may
be a number of additional publications:
▸ Geographical variance in patterns of disease, QoL
and patient choices;
Table 3 Study groups
WW Patients with an aneurysm considered to be at a low risk of rupture will be started on prophylactic therapy as per
internationally accepted guidelines detailed below. However, they will remain under surveillance in the form of an
annual CT scan/MRI and MDT review. These patients’ data will contribute to the natural history component of our
study
BMT Patients who are considered unsuitable for elective ESG/OSR, or who refuse ESG or OSR, will be assigned to best
medical therapy. This will follow international guidelines11 which recommend control of hypertension (BP<140/90 or
130/80 mm Hg for patients with diabetes or renal impairment), lipid profile optimisation (target cholesterol <70 mg/dL),
smoking cessation and other atherosclerotic risk-reduction measures to reduce the risk of stroke, MI, heart failure and
cardiovascular death. We recognise that patients who initially elect for a conservative option may later change their
opinion and this will be captured as a crossover from BMT to ESG/OSR
ESG Endovascular repair of the aneurysm via transluminal introduction of a stent-graft under X-ray guidance. Hybrid
procedures that comprise a combination of a conventional surgical component and a transluminal repair are also
included in this group since the aim of such techniques is to minimise the overall invasive nature of repair
OSR These patients will undergo replacement of the aneurysmal aorta with a prosthetic conduit via a sternotomy or
thoracotomy with circulatory support
BMT, best medical therapy; BP, blood pressure; ESG, endovascular stent grafting; MDT, multidisciplinary team; MI, myocardial infarction;
OSR, open surgical repair; WW, watchful waiting.
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▸ Inﬂuence of waiting lists for ESG versus OSR on QoL;
▸ Statistical methodology for estimation of aneurysm
growth from multiple related but different evidence
sources;
▸ Methods for robust cost-effectiveness comparisons in
the absence of clinical trial data.
Papers regarding current and future decision-making
will arise from our planned Delphi exercise.12 The
process will be in two stages, each comprising two rounds.
The ﬁrst stage of the exercise will be conducted at the
beginning of the study and is aimed at charting existing
practice and the prevailing concepts underpinning that
practice. The second stage is conducted when results of
the observational study are available for dissemination.
The aim of this stage is to develop consensus regarding
the most appropriate method of managing CTAA in the
UK. Participants will be drawn to represent as wholly as
possible the existing service provision with no regard to
perceived or established treatment or referral biases since
that gives the best potential to realise the aims of both
stages of the exercise. The exercise will be conducted
using RAND methodology.12 The ﬁrst rounds of both
stages will be conducted electronically with an estimated
total of 108 case vignettes representing combinations of
different morphological, age, ﬁtness and connective
tissue factors. The second rounds will require fewer case
vignettes and will be conducted as workshops in conjunc-
tion with a national conference.
The ﬁndings from this study will be reported locally,
nationally and internationally in the form of presenta-
tions and papers to medical professionals as well as
patient groups. This information will also be available
Table 4 data to be collected from study patients
Patient factors Aneurysm factors Outcomes
Gender Connective tissue disorder Technical outcomes
Age Presenting symptoms of aneurysm Treatment (BMT/ESG/OSR)
Height Extent of aneurysm Reoperation for bleeding
Weight Aortic diameter immediately proximal to
aneurysm
Access vessel injury
Hypertension Aortic diameter immediately distal to aneurysm Endoleak
Diabetes mellitus Maximum diameter of thoracic aorta on
presentation
Endoleak treatment
Smoking history Aneurysm length Conversion to open surgery
LV function Proximal neck length Infection
Coronary artery disease Distal neck length Fistulae
Valvular heart disease Reintervention
COPD Aneurysm growth rate
Creatinine Clinical outcomes
Previous neurovascular injury Death
Extracardiac arteriopathy CVA (neuro deficit >48 h)
Logistic Euroscore Myocardial infarction
Previous cardiac/aortic
intervention
Mechanical respiratory support >48 h
Family history of aneurysm Renal replacement therapy
Living status Paraplegia
EQ-5D-5L DVT/PE
EQ-5D-5L
Cost outcomes
Operating room time
Hybrid theatre time
Prosthesis
Blood products
ICU days
HDU days
Ward days (preoperative
+postoperative)
Medications
Investigations in-hospital
Outpatient visits
Outpatient investigations
Treatment of complications
Primary care visits
BMT, best medical therapy; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; DVT, deep vein thrombosis; ESG,
endovascular stent grafting; HDU, high-dependency unit; ICU, intensive care unit; LV, left ventricle; OSR, open surgical repair; PE, pulmonary
embolism.
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via patient information leaﬂets and the study website
which will be designed with the help of our patient
representatives.
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